 "Cipla shares gain over 5 pc; m-cap rises by Rs 3,021 cr")
Shares of drug firm Cipla on Friday gained over 5 per cent after the company said it has received the final approval from the US health regulator for Dimethyl Fumarate capsules.
The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.
On the NSE, it gained 4.99 per cent to settle at Rs 770.10.
The company's market valuation also rose by Rs 3,021.11 crore to Rs 62,104.11 crore.
The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera.
Cipla
